Posted Aug. 29, 2012 at 5:22 a.m.

Premium Lock Novartis experimental heart-failure drug shows promise

Published: 2012-08-29 05:22:25
Updated: 2012-08-29 05:22:25

Heart research Heart research

If successful, LCZ696 would be the first drug for patients with preserved ejection fraction, a condition in which the organ's ventricles still pump out more than 40 percent of the blood that comes in, but the atrium chamber fails to supply enough blood to the ventricle to meet the body's needs. The condition, which mainly affects women, accounts for about half of all heart failure patients....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 Bloomberg. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll